ADC Therapeutics S.A. ADCT NYSE

ADC Therapeutics S.A. (ADCT) reported total assets of $323.15M and total liabilities of $508.98M for fiscal year 2025, resulting in total equity of $-185.83M.

The company held $261.34M in cash and short-term investments. Total debt stood at $439.01M, with net debt of $177.67M. The Debt-to-Equity (D/E) ratio was -2.36 (conservative).

Current ratio is 4.37, indicating strong short-term liquidity. Interest coverage is -2.1x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (35/100) — Total assets $323.15M and equity $-185.83M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity -2.36 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 39/100 with 2/7 criteria passed.

RVMD

Revolution Medicines, Inc.

$147.01

+7.86%

PTGX

Protagonist Therapeutics, Inc.

$104.72

+7.33%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

CRNX

Crinetics Pharmaceuticals, Inc.

$39.75

+2.82%

ALMS

Alumis Inc. Common Stock

$22.89

+1.64%

RARE

Ultragenyx Pharmaceutical Inc.

$24.57

+3.98%

STOK

Stoke Therapeutics, Inc.

$35.86

+2.31%

RAPT

RAPT Therapeutics, Inc.

$58.01

+0.00%